Human APOBEC3C (aa 23-49) Control Fragment Recombinant Protein | Invitrogen RP-107823 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

protein

product name :

Human APOBEC3C (aa 23-49) Control Fragment Recombinant Protein

catalog :

RP-107823

quantity :

100 uL

price :

US 259.00

product information

Product Type :

Protein

Product Name :

Human APOBEC3C (aa 23-49) Control Fragment Recombinant Protein

Catalog # :

RP-107823

Quantity :

100 uL

Price :

US 259.00

Clonality :

Recombinant

Purity :

purified

Reactivity :

Human

Applications :

Blocking Assay: Assay-dependent, Control: Assay-dependent

Species :

Human

Storage :

-20 C, Avoid Freeze/Thaw Cycles

Description :

APOBEC (apolipoprotein B mRNA editing enzyme, catalytic) proteins inhibit retroviruses by deaminating cytosine residues of viral RNA and DNA. The seven APOBEC3 genes or pseudogenes are found in a cluster thought to result from gene duplication on chromosome 22. Like APOBEC3G, APOBEC3F deaminates deoxycytosine to deoxyuracil in the minus strand of HIV-1 DNA, resulting in G to A hypermutation in the plus strand of DNA. Thus, APOBEC3G and APOBEC3F provide a mechanism for innate immunity to retroviruses, and are also likely contribute to sequence variation observed in many viruses. Viral infectivity factor (Vif) imparts APOBEC3G and APOBEC3F resistance to HIV through impaired translation of their mRNA and accelerated posttranslational degradation of the APOBEC3 proteins by the 26S proteasome. Interestingly, HIV-1 Vif cannot form a complex with APOBEC3G or APOBEC3F of mouse origin as it does with the human protein, and thus mouse APOBEC3G and APOBEC3F function as a potent inhibitors of wildtype HIV-1 replication, where human APOBEC3G and APOBEC3F are only able to inhibit Vif-deficient HIV-1 replication. This implies that induction of APOBEC3G and APOBEC3F activity or a method of blocking their interaction with Vif may provide a method for therapeutic intervention.

Format :

Liquid

Applications w/Dilutions :

Blocking Assay: Assay-dependent, Control: Assay-dependent

Aliases :

A3C; APOBEC1L; APOBEC1-like; APOBEC3C; apolipoprotein B editing enzyme catalytic polypeptide-like 3C; apolipoprotein B mRNA editing enzyme catalytic polypeptide like 3C; apolipoprotein B mRNA editing enzyme catalytic subunit 3C; apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3C; ARDC2; ARDC4; ARP5; bK150C2.3; DNA dC->dU-editing enzyme APOBEC-3C; MGC19485; PBI; Phorbolin I; probable DNA dC->dU-editing enzyme APOBEC-3C